LigaChem Biosciences Inc.

Equities

A141080

KR7141080002

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
66,700 ^KRW	-2.49%		-2.06%	+2.62%

Apr. 08	NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024	CI
Mar. 29	Pan Orion Corp. Ltd. completed the acquisition of 4.93% stake in LegoChem Biosciences, Inc. from Kim Yong Ju and Park Se Jin.	CI

LegoChem Biosciences, Amgen in Licensing Agreement

December 23, 2022 at 07:34 am EST

By Chris Wack

LegoChem Biosciences Inc. said Friday that it has entered into a research collaboration and license agreement with Amgen Inc.

Under the deal, Amgen was granted rights to research, develop and commercialize antibody-drug conjugates directed against up to five targets selected by Amgen based on LegoChem's proprietary ConjuAll ADC technology.

LegoChem is eligible to receive up to $1.25 billion in payments and is also eligible for tiered royalties as a percentage of worldwide commercial sales by Amgen.

LegoChem said its clinical-stage ConjuAll ADC technology platform provides optimized site-specific conjugation, as well as cancer-selectively activating linker and payload technologies for ADCs.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

12-23-22 0733ET

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	LIGACHEM BIOSCIENCES INC.	66,700 KRW	-2.49%	-2.06%	1.75B
	AMGEN INC.	310.2 USD	-0.87%	-0.37%	166B

Latest news about LigaChem Biosciences Inc.

NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024	Apr. 08	CI
Pan Orion Corp. Ltd. completed the acquisition of 4.93% stake in LegoChem Biosciences, Inc. from Kim Yong Ju and Park Se Jin.	Mar. 28	CI
LegoChem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Samsung Biologics Collaborates with LegoChem Biosciences on ADC Development and Manufacturing	Feb. 09	MT
Orion Set to Acquire 25% Stake in LegoChem Biosciences	Jan. 17	MT
South Korean Shares Close Lower Amid Geopolitical Tension	Jan. 16	MT
Legochem Biosciences to Raise 469.8 Billion Won through Rights Issue; Shares Fall 5%	Jan. 15	MT
LegoChem Biosciences, Inc. announced that it expects to receive KRW 1018.327793998 billion in funding from Pan Orion Corp. Ltd.	Jan. 14	CI
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.	Dec. 27	CI
LegoChem Biosciences, Inc.'s Equity Buyback announced on June 28, 2023, has expired with 140,000 shares, representing 0.53% for KRW 4,879.08 million.	Dec. 27	CI
J&J: licensing agreement with Korea's LegoChem in ADCs	Dec. 27	CF
Legochem Biosciences Announces License Agreement for Lcb84 Trop2-Targeted ADC	Dec. 25	CI
LegoChem Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
BostonGene and LegoChem Biosciences, Inc. Announce Collaboration to Support Phase I/II Study of LCB84, TROP2-Directed ADC, in Patients with Advanced Cancers	Nov. 07	CI
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.	23-10-04	CI
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.	23-10-04	CI
Bridge Biotherapeutics, Inc. announced that it has received KRW 5.9999904 billion in funding from LegoChem Biosciences, Inc.	23-09-04	CI
Bridge Biotherapeutics, Inc. announced that it expects to receive KRW 5.9999904 billion in funding from LegoChem Biosciences, Inc.	23-08-27	CI
LegoChem Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
LegoChem Biosciences, Inc. announces an Equity Buyback for KRW 5,000 million worth of its shares.	23-06-28	CI
LegoChem Biosciences, Inc. authorizes a Buyback Plan.	23-06-27	CI
LegoChem Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
LegoChem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-23	CI
LegoChem Biosciences, Amgen in Licensing Agreement	22-12-23	DJ
Legochem Biosciences and Amgen Enter into A Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates	22-12-23	CI

Chart LigaChem Biosciences Inc.

Duration

Period

More charts

Company Profile

LigaChem Biosciences Inc, formerly LegoChem Biosciences Inc, is a Korea-based biotechnology company mainly engaged in development and discovery of new pharmaceuticals based on medical chemistry. The Company principally involves in the development of new drugs, including antibiotics, anticoagulants, anticancer, antiplatelet, anti-inflammatory, as well as antibody-drug-conjugates (ADC), among others. The Company provides technology transfer, joint and contact research and research services. In addition, the Company sells pharmaceutical products.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for LigaChem Biosciences Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
LIGACHEM BIOSCIENCES INC.	+2.62%	1.75B
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs